New opt-in patient registry for psychedelic based therapy

Magic Mushrooms in laboratory. Psilocybin science and research. Person examining fungi.

A new national patient registry will help inform the effectiveness and safety of prescribing psychedelic substances to patients with serious mental health conditions including depression and post-traumatic stress disorder (PTSD).


It follows the Therapeutic Goods Administration (TGA)’s decision to allow authorised psychiatrists to prescribe medicines containing the psychedelic substances MDMA (ecstasy) and psilocybin, a compound found in magic mushrooms, to treat PTSD and treatment-resistant depression. The changes came into effect on 1 July 2023.

The Pharmacotherapy and Psychedelic registry will be developed and led by researchers at the Australian National University (ANU). Its aim is to collect health data from patients nationwide with the goal of improving patient care and health outcomes, and advancing health policy and research.

Evidence of the efficacy of MDMA and psilocybin is rapidly emerging, but their use is not yet well established, said Director of the ANU School of Medicine and Psychology Professor Paul Fitzgerald.

Gathering information around the potential benefits and how effective patients find these substances will be important, he said.

“Psychiatrists prescribing the treatment will refer patients to us, and if or when patients have provided their consent, they’ll be sent a series of questionaries.

“We’re interested in finding out what their experience was like, but also whether there have been any specific changes in their thinking as a result of the treatment they received.”

The registry will also help determine whether there are any safety issues with the therapeutic use of these psychedelic substances in the long term, Professor Fitzgerald said.

“The registry should also give us a better idea of whether the use of these substances as a potential therapy will be more successful in some patients than others,” he said.

“We really want to understand how the treatment is working, not just whether it is working. Our aim is to eventually have hundreds, if not thousands, of patients opt-in, giving us a very rich dataset to work with.”

The registry is supported by the National Health and Medical Research Council and Mind Medicine Australia.

Leave a Reply

Your email address will not be published. Required fields are marked *

Want more? Read the latest issue of ANMJ

APR-JUN 2024 ISSUE OUT NOW!

Categories

Advertise with ANMJ

The ANMJ provides a range of advertising opportunities within our printed monthly journal and via our digital platforms.